Skip to main content
. 2021 Apr 15;11(3):733–750. doi: 10.1007/s13555-021-00517-9
Evidence on efficacy of Janus kinase inhibitors in patients with interpheronopathies is scarce and of low methodological quality.
Future clinical trials should use validated scales and report drug safety in a more accurate way.